NANOBIOTIX (EPA:NANO)

PRESS RELEASE

published on 10/31/2025 at 08:00, 4 months 17 days ago

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Nanobiotix announces $71M strategic royalty monetization agreement with Healthcare Royalty, extending cash runway and enabling long-term growth in cancer treatment

Cancer Treatment HealthCare Royalty Financial Agreement NANOBIOTIX Royalty Monetization
BRIEF

published on 10/01/2025 at 22:20, 5 months 15 days ago

NANOBIOTIX Reveals Promising Phase 1 Study Results for Esophageal Cancer Treatment

Phase 1 Study Radiotherapy Adverse Events JNJ-1900 (NBTXR3) Esophageal Cancer
PRESS RELEASE

published on 10/01/2025 at 22:15, 5 months 15 days ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Nanobiotix announces first data from Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with esophageal cancer. Results presented at ASTRO 2025 Annual Meeting

NANOBIOTIX Phase 1 Study JNJ-1900 Esophageal Cancer ASTRO
BRIEF

published on 09/30/2025 at 22:20, 5 months 16 days ago

Nanobiotix: Financial results and clinical progress in the first half of 2025

Financial Results Biotechnology NANOBIOTIX Johnson & Johnson JNJ-1900
PRESS RELEASE

published on 09/30/2025 at 22:15, 5 months 16 days ago

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Nanobiotix provides business update & reports 2025 half year financial results. Highlights clinical development program & financial performance

Financial Results Financial Performance Business Update Clinical Development NANOBIOTIX
BRIEF

published on 09/30/2025 at 00:35, 5 months 17 days ago

NANOBIOTIX Reports Promising Phase 1 Results for JNJ-1900 (NBTXR3) in R/M-HNSCC

Phase 1 Trial NANOBIOTIX Clinical Study Results R/M-HNSCC JNJ-1900 (NBTXR3)
PRESS RELEASE

published on 09/30/2025 at 00:30, 5 months 17 days ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Nanobiotix announces updated phase 1 results supporting JNJ-1900 plus anti-PD-1 as a new option in R/M-HNSCC. Promising local and systemic responses presented at ASTRO 2025

NANOBIOTIX Anti-PD-1 JNJ-1900 R/M-HNSCC ASTRO 2025
BRIEF

published on 09/17/2025 at 22:20, 5 months 29 days ago

New Positive Results for NANOBIOTIX in Phase 1 Melanoma Study

Efficiency Melanoma NANOBIOTIX Phase 1 JNJ-1900
PRESS RELEASE

published on 09/17/2025 at 22:15, 5 months 29 days ago

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Nanobiotix announces new results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors as a 2L+ therapy for patients with primary cutaneous melanoma resistant to anti-PD-1. Favorable safety profile and early efficacy signals observed

Melanoma NANOBIOTIX Immune Checkpoint Inhibitors Phase 1 Study JNJ-1900
BRIEF

published on 09/12/2025 at 19:05, 6 months 5 days ago

Nanobiotix Announces Voting Rights and Share Capital Details

Voting Rights Shares Euronext Nasdaq NANOBIOTIX

Published on 03/17/2026 at 13:30, 6 hours 34 minutes ago

Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 6 hours 34 minutes ago

Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 7 hours 4 minutes ago

Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 13:00, 7 hours 4 minutes ago

High-Resolution Airborne Survey Completed at Music Valley HREE Project
Published on 03/17/2026 at 12:30, 7 hours 34 minutes ago

Revival Gold Targets Underground Resource Growth With Drilling at Beartrack-Arnett Gold Project in Idaho

View all ACCESSWIRE

Published on 03/17/2026 at 18:07, 1 hour 57 minutes ago

POS-Transaction in Own Shares
Published on 03/17/2026 at 17:58, 2 hours 6 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 17:45, 2 hours 19 minutes ago

FIGEAC AÉRO: THREE NEW WINS IN MEXICO
Published on 03/17/2026 at 15:30, 4 hours 34 minutes ago

Original-Research: Desert Gold Ventures Inc. (von GBC AG): Buy
Published on 03/17/2026 at 15:19, 4 hours 45 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC

View all EQS

Published on 03/17/2026 at 07:00, 13 hours 4 minutes ago

Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 2 hours ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 2 hours ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 2 hours ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 1 day 2 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News